Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Integrate seizure control, fetal and parental reproductive safety, contraception interactions and pregnancy pharmacokinetics through planned specialist care while preventing abrupt antiseizure medicine withdrawal.
Preconception care aims to achieve the best attainable seizure control on the safest effective regimen before organogenesis. Review whether epilepsy and seizure classification remain secure, how long seizure freedom has lasted, previous medicine failures, dose, adherence and SUDEP risk. Explain known and uncertain fetal effects in absolute terms where reliable data exist. A planned change may take months because cross-titration must preserve control; contraception therefore remains important until the new regimen is stable and specialist review is complete.
Contraception cannot be separated from pharmacology. Carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine and some topiramate exposure can induce metabolism and impair selected hormonal methods. Long-acting intrauterine contraception and depot medroxyprogesterone are not affected in the same way, but suitability is individual. Combined oestrogen-containing contraception can substantially lower lamotrigine levels and concentrations may rise during the hormone-free interval. Emergency contraception after enzyme-inducing medication requires same-day FSRH-aligned advice, with a copper intrauterine device often the most effective unaffected option.
A contraception review, annual epilepsy appointment, new relationship or request for folic acid should prompt early discussion of medicine risk and specialist planning before conception.
New seizures can follow falling drug concentrations, vomiting, missed doses, sleep deprivation or pregnancy-specific pathology and need prompt multidisciplinary assessment rather than automatic dose escalation.
A seizure after 20 weeks or postpartum, particularly with hypertension, headache, visual symptoms, epigastric pain or proteinuria, requires immediate obstetric treatment even in someone with established epilepsy.
Breakthrough bleeding, starting or stopping an enzyme inducer, or changing an oestrogen-containing method can signal altered contraceptive or lamotrigine exposure and needs timely specialist pharmacy advice.
Rapid pharmacokinetic reversal, sleep deprivation, missed medicines and unsupervised bathing or carrying can combine after birth, making a written dose and infant-safety plan essential.
Start before pregnancy where possible and do not delay epilepsy review. Confirm ongoing need after 12 weeks, check other supplements to avoid duplication and explain that adherence to antiseizure treatment remains important.
Clearance commonly rises during pregnancy and returns rapidly postpartum, creating breakthrough then toxicity risks. Oestrogen contraception also lowers exposure; titration and rash precautions remain essential.
Avoiding teratogenic exposure matters, but destabilising effective therapy can produce tonic-clonic seizures, trauma, hypoxia and SUDEP risk; both sides belong in the same decision.
An inducer may reduce hormonal contraceptive protection, while an oestrogen-containing method may reduce lamotrigine concentration and alter seizure control.
A concentration associated with seizure freedom before conception can guide pregnancy adjustment more usefully than chasing a generic reference range.
Epilepsy alone does not dictate caesarean birth, but regular dosing, hydration, sleep, analgesia and an emergency plan should be protected around labour.
The safest plan anticipates rapid medicine-clearance changes, fragmented sleep and practical risks such as bathing or carrying an infant if awareness could be lost.
Telling someone to stop valproate, topiramate or another antiseizure medicine immediately after a positive test can precipitate dangerous breakthrough seizures.
Assuming all hormonal contraception works normally with every antiseizure medicine risks both unintended pregnancy and altered seizure control.
Waiting until pregnancy to change a stable complex regimen compresses titration into the period when both seizures and fetal exposure are most consequential.
Increasing lamotrigine through pregnancy without a documented postpartum reduction plan can cause dizziness, diplopia and ataxia as clearance returns.
Discussing infant malformation risk while omitting maternal SUDEP, driving, sleep and injury risks produces an unbalanced consent conversation.
Your practice draft is saved in this browser.
A patient with epilepsy taking lamotrigine reports a positive home pregnancy test and asks whether to stop treatment immediately because of concern about the baby. What is the safest advice?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Ensure highly effective contraception, pregnancy exclusion before initiation and documented annual review. It can interact with hormonal contraception; after a positive pregnancy test for epilepsy, obtain urgent advice and do not stop abruptly.